Considering that the upregulated VDR expression and the inhibition of cell proliferation upon VDR knockdown in CML were independent of BCR::ABL1 mutations, we investigated whether inhibiting VDR could overcome the resistance of CML to TKIs in vivo. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.